Table 1

Sensitivities and specificities of the Vidas and Liaison VCA IgM assaysa

Expected EBV status in referenced assayVidas VCA IgMLiaison VCA IgMLiaison minus Vidas (%) (95% CI)
Sensitivity or specificity (%)b (95% CI)False neg or pos (no.)Eq (no.)Sensitivity or specificity (%)b (95% CI)False neg or pos (no.)Eq (no.)
Early primary infection (n = 53)74.5 (62.8–86.2)13076.5 (65.1–87.9)662.0 (−10.29 to 14.19)
Primary infection (n = 133)91.5 (86.8–96.2)8393.9 (89.8–98.0)172.4 (−3.24 to 8.13)
Total (n = 186)86.7 (81.8–91.6)21389.0 (84.5–93.5)7132.3 (−2.88 to 7.41)
Past infection (n = 183)95.0 (91.8–98.2)5492.9 (89.2–96.6)58−2.1 (−6.57 to 1.90)
EBV seronegative (n = 157)97.5 (95.1–99.9)3193.6 (89.8–97.4)37−3.9 (−8.70 to 0.46)
Total (n = 340)96.2 (94.2–98.2)8593.2 (90.5–95.9)815−3.0 (−5.99 to −0.16)*
  • a False neg or pos, false negative (with early primary and primary infection samples) or false positive (with past infection or EBV-seronegative samples); no., number of samples; Eq, equivocal (considered false positive for specificity and false negative for sensitivity); CI, confidence interval; *, statistically significant.

  • b Percentages for samples from patients with past infections and EBV-seronegative samples are percent specificities. Percentages for the other samples are percent sensitivities.